Delving into the Latest Updates on Pembrolizumab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Lambrolizumab, Pembrolizumab (Genetical Recombination), Pembrolizumab (genetical recombination) (JAN)

+ [12]

Target

PD-1

Action

inhibitors

Mechanism

PD-1 inhibitors(Programmed cell death protein 1 inhibitors)

Therapeutic Areas

NeoplasmsImmune System DiseasesInfectious Diseases+ [13]

Active Indication

Carcinoma of urinary bladder, invasivePlatinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+ [323]

Inactive Indication

Acral Lentiginous Malignant MelanomaAcute Myeloid LeukemiaAcute myeloid leukemia with mutated NPM1+ [122]

Originator Organization

Merck & Co., Inc.

Active Organization

Merck Sharp & Dohme LLC

MSD R&D (China) Co. Ltd.

Merck Sharp & Dohme Corp.

+ [16]

Inactive Organization

Merck Sharp & Dohme (Ireland) Ltd.

Turnstone Biologics Corp.

Viralytics Pty Ltd.

License Organization

Nektar Therapeutics

NeoImmuneTech, Inc.

Canada Pension Plan Investment Board

+ [80]

Drug Highest PhaseApproved

First Approval Date

United States (04 Sep 2014),

Melanoma

RegulationPriority Review (United States), Breakthrough Therapy (United States), Accelerated Approval (United States), Orphan Drug (United States), PRIME (European Union), Priority Review (China), Breakthrough Therapy (China), Orphan Drug (Japan), Orphan Drug (Australia), Priority Review (Australia), Conditional marketing approval (China)

Login to view timeline

Structure/Sequence

Sequence Code 93660H

Source: *****

Sequence Code 93670L

Source: *****

This is a single center, open-label phase I clinical trial designed to determine the safety of personalized and adjusted neoantigen peptide vaccine (PANDA-VAC) administered concurrently with pembrolizumab in subjects with advanced squamous non-small cell lung cancer (NSCLC) or squamous cell carcinoma of head and neck (SCCHN).

Start Date20 May 2027

Sponsor / Collaborator

Lineberger Comprehensive Cancer Center

NCT07689240

/ Not yet recruitingPhase 3IIT

Phase III Study of Adjuvant Pembrolizumab vs Active Surveillance After Nephrectomy in Patients With Non-Clear Cell Renal-Cell Carcinoma

This phase III trial compares the effect of pembrolizumab to active surveillance after a surgical procedure to completely or partially remove a kidney (nephrectomy) in improving time without disease in patients with non-clear cell renal cell cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab after nephrectomy may be more effective than the usual active surveillance approach for improving time without disease in patients with non-clear cell renal cell cancer.

Start Date10 Feb 2027

Sponsor / Collaborator

National Cancer Institute

ACTRN12626000937314

/ Not yet recruitingPhase 2IIT

IMPACT - A phase 2 study of IMmunotherapy with Pembrolizumab and sACituzumab Tirumotecan in pMMR recurrent or advanced endometrial cancer

Start Date01 Feb 2027

Sponsor / Collaborator-

100 Clinical Results associated with Pembrolizumab

Login to view more data

100 Translational Medicine associated with Pembrolizumab

Login to view more data

100 Patents (Medical) associated with Pembrolizumab

Login to view more data

11,519

Literatures (Medical) associated with Pembrolizumab

31 Dec 2026·Human Vaccines & Immunotherapeutics

Durable response of anaplastic thyroid cancer to pembrolizumab combined with chemotherapy: A case report

Article

Author: Zhuang, Yihan ; Chen, Qiongshan ; Lin, Wen ; Chen, Zipei

Anaplastic thyroid cancer is a notoriously aggressive malignancy with a dismal prognosis, typically associated with a median overall survival of less than one year. Therapeutic alternatives are particularly limited for patients without actionable driver mutations. Here, we report a case of BRAF V600E wild-type, PD-L1-positive (tumor proportion score of 80%) anaplastic thyroid cancer with residual/relapsed disease following surgery and subsequent progression on multi-targeted tyrosine kinase inhibitor therapy. The patient was thereafter treated with a combination of pembrolizumab, nab-paclitaxel and carboplatin, resulting in a sustained near-complete response lasting over 30 months, accompanied by a manageable safety profile. The favorable response in this case suggests that further evaluation of this triplet regimen could be considered for anaplastic thyroid cancer, though this remains a speculative premise requiring validation. Further studies are also needed to clarify the underlying mechanisms of this combination and to identify predictive biomarkers for patient selection.

31 Dec 2026·INTERNATIONAL JOURNAL OF HYPERTHERMIA

Focused ultrasound ablation surgery combined with immune checkpoint inhibition in driver-gene wild-type NSCLC with liver metastasis: a feasibility study

Article

Author: Wang, Ting ; Chen, Jinyun ; Ouyang, Bing ; Chen, Li ; Chen, Wenzhi

BACKGROUND:

This single-arm, open-label clinical trial aimed to evaluate the preliminary safety, efficacy and feasibility of focused ultrasound ablation surgery (FUAS) sequential with immune checkpoint inhibitors (ICIs) in patients with driver-gene wild-type non-small cell lung cancer (NSCLC) and liver metastases.

MATERIALS AND METHODS:

Ten eligible patients received two cycles of FUAS sequential with ICIs. The ICIs used include Camrelizumab (7/10), Pembrolizumab (3/10) and Serplulimab used for immune rechallenge (1/10). Follow-up was conducted every 6 weeks ± 3 days, including imaging and hematological assessments. Treatment-related adverse events (AEs) were documented anytime.

RESULTS:

All participants demonstrated stable tolerability and safety in this trial. Immediate post-FUAS ablation rates ranged from 73% to 80%. The median follow-up time is 84 days (IQR, 42-127 days). From baseline to week 18, continuous shrinkage of both hepatic metastatic and target lesions was observed. The DCR of the tumor has reached 80% since the 2nd follow-up (12 weeks), and it remains at 50% until the 4th follow-up (24 weeks).

CONCLUSION:

FUAS sequential with ICIs suggests preliminary safety, activity and feasibility in treating driver-gene wild-type NSCLC patients with liver metastases, further validation is needed.

31 Dec 2026·Human Vaccines & Immunotherapeutics

Mapping research trends in esophageal cancer immunotherapy: A decade of thematic evolution and emerging priorities

Review

Author: Zang, Qiwei ; Jia, Huijun ; Wei, Hongyu ; Gong, Yifan ; Zhao, Chengguang

Immunotherapy has become a pivotal therapy for various cancers, including esophageal cancer, showing promising potential in improving survival rates and enabling personalized care. However, significant challenges occur in identifying predictive biomarkers, refining combination therapies, and managing immunotherapy-related adverse effects. This bibliometric study analyzed publications related to the use of immunotherapy in esophageal cancer management over a 10-y period (January 1, 2015, to October 14, 2024), retrieved from the Web of Science Core Collection. Keyword co-occurrence and co-citation analyses were performed to identify key contributors, central themes, and influential publications. A total of 545 publications on esophageal cancer immunotherapy were included in the analysis. A sharp increase in publication volume was observed beginning in 2019, with a peak between 2021 and 2023. China emerged as the leading contributor, accounting for 67.7% of the total output, while Zhengzhou University produced the highest number of publications among all institutions. Prominent individual contributors included Ken Kato and Shen Lin. Research hotspots centered on PD-1/PD-L1 inhibitors, combination therapies, and tumor microenvironment modulation. Notably, a clear temporal evolution in research focus was observed, with early studies emphasizing specific immune checkpoint targets and agents (e.g., PD-1, Pembrolizumab, and CTLA-4), followed by a shift toward mechanistic investigations involving the tumor microenvironment, treatment resistance, and prognosis. This study provides a comprehensive view of immunotherapy in the management of esophageal cancer, offering direction for future research and valuable insights for clinical innovation.

7,100

News (Medical) associated with Pembrolizumab

03 Sep 2026

·www.prnewswire.com

Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab) in the US

MUMBAI, India and WARREN, N.J., Sept. 3, 2026 /PRNewswire/ -- Invagen Pharmaceuticals Inc, a wholly owned subsidiary of Cipla Limited (BSE: 500087) (NSE: CIPLA) today announced that it has entered into a strategic partnership with Qilu Pharmaceutical Co., Ltd. (hereinafter referred to as Qilu), for the exclusive licensing and supply of QL2107, a biosimilar to Keytruda® (pembrolizumab), for the United States As part of the agreement, Qilu will be responsible for development, regulatory registration and supply of the product while Cipla USA Inc. will be responsible for the commercialization of the asset by leveraging its strong commercial presence in the defined territory. The collaboration reflects both companies' shared commitment to addressing the growing burden of cancer and improving access to advanced biologic therapies. Commenting on the partnership, Achin Gupta, Managing Director & Global Chief Executive Officer, Cipla, said, "This partnership reflects Cipla's confidence in the long-term potential of biosimilars and supports our strategy to build a strong oncology-focused portfolio. By combining Qilu's development strengths with Cipla's commercial presence and patient-centric legacy, we aim to expand access to high-quality biologics for patients across our focus markets." Marc Falkin, Chief Executive Officer, Cipla North America, said, "This collaboration is aligned with our strategy to expand our biosimilar portfolio in the coming fiscal years, and we are excited to add QL2107 with Qilu who have been great partners. With our established commercial capabilities, we are well-positioned to successfully launch QL2107, subject to regulatory approval, and help ensure it reaches patients in need while lowering the cost of treatment." Hanchang Zhang, General Manager of Qilu Pharmaceutical, said, "We are pleased to establish this partnership with Cipla for QL2107. Qilu boasts a robust and growing biosimilar product pipeline. By combining our R&D and manufacturing strengths with Cipla's U.S. commercial expertise, we aim to bring a high-quality, affordable pembrolizumab biosimilar to U.S. patients." About Cipla Limited Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, antiretroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 48 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 70+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Jun'26), 2nd Largest in the pharma prescription market in South Africa (IQVIA MAT May'26), and 2nd largest by prescription in the US Gx (Repulses + MDI) products (IQVIA MAT Jun'26). For nine decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the center of the HIV movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit , or click on Twitter, Facebook, LinkedIn. About Qilu Established in 1958, Qilu Pharmaceutical is now one of the leading vertically integrated pharmaceutical companies in China that develops, manufactures and distributes both Finished Dosage Forms (FDFs) and Active Pharmaceutical Ingredients (APIs). Qilu currently has 11 domestic manufacturing sites and employs more than 38,000 people worldwide. In 2025 Qilu ranked among the Top 3 enterprises in China's pharmaceutical industry. Dedicated to offering high-quality & trustworthy medicines to the world and improving people's well-being, Qilu is vigorously exporting its products to over 110 countries and regions around the world. To date, Qilu has secured 58 ANDA approvals from the U.S. FDA, with 28 formulations launched in the EU and the United Kingdom. Its robust pipeline includes over 50 biosimilars, 130-plus innovative drugs and more than 200 generic drug candidates in-development. SOURCE Cipla 21% more press release views with Request a Demo

License out/inDrug ApprovalBiosimilar

03 Sep 2026

·firstwordpharma.com

Lung cancer study that started hype for Summit, Akeso's ivonescimab hits survival goal

Two years after Summit Therapeutics and partner Akeso disclosed the first detailed head-to-head data for the PD-1/VEGF bispecific antibody ivonescimab versus Merck & Co.'s PD-1 inhibitor Keytruda (pembrolizumab), the companies have now reported overall survival (OS) findings from the same study. Progression-free survival (PFS) results from the Phase III HARMONi-2 trial were presented at the World Conference on Lung Cancer (WCLC) in 2024, showing that ivonescimab reduced the risk of disease progression or death by 49% compared with Keytruda when used as a first-line treatment in Chinese patients with PD-L1 positive advanced non–small-cell lung cancer (NSCLC). The findings were first alluded to a few months earlier, when Summit said that HARMONi-2 hit its primary endpoint of PFS, leading to the company's shares more than tripling. Now, the companies have reported that the study achieved its key secondary endpoint of OS at a pre-specified interim analysis, with ivonescimab demonstrating a statistically significant and clinically meaningful improvement over Keytruda. No specific figures were disclosed, but they are expected to be presented at a future medical conference.PFS results from HARMONi-2 supported approval of ivonescimab in China last year in first-line, PD-L1-positive NSCLC without EGFR or ALK mutations.Meanwhile, seeking to replicate these findings beyond Chinese patients, Summit is currently conducting the Phase III HARMONi-7 trial in a number of countries, including the US and Europe, in patients with PD-L1 high-expressing NSCLC.Ivonescimab is also approaching its first key date at the FDA, with the regulator set to decide by November 14 whether to approve the therapy, in combination with chemotherapy, in people with EGFR-mutated non-squamous NSCLC following progression on an EGFR tyrosine kinase inhibitor (TKI). The filing is based on results from the Phase III HARMONi trial, in which ivonescimab plus platinum-doublet chemotherapy reduced the risk of disease progression or death by 48% compared to chemotherapy alone in EGFR-mutated patients with locally advanced or metastatic non-squamous disease previously treated with a third-generation EGFR TKI.

Phase 3Clinical ResultDrug ApprovalNDA

03 Sep 2026

·www.biospace.com

Summit, Akeso’s ivonescimab bests Merck’s Keytruda in China trial—again

iStock, TeamDAF New Phase 3 data show that Summit Therapeutics and Akeso’s PD-1/VEGF therapy improved overall survival in patients with a type of lung cancer as compared to Merck’s Keytruda but the results will need to be replicated in non-Chinese patients. Summit Therapeutics and Akeso’s upcoming PD-1/VEGF bispecific antibody has officially bested Merck’s mega-blockbuster Keytruda on both overall survival and progression free survival in a type of non-small cell lung cancer. The latest results for the partners could establish a new paradigm in NSCLC treatment where ivonescimab becomes the regimen of choice among oncologists, analysts said. But the new data from the Phase 3 HARMONi-2 trial comes from Chinese clinical trials. Summit still has to verify the results in Western patients to get the FDA on board for a clean regulatory review. Akeso on Thursday announced interim results from the Phase 3 HARMONi-2 trial, which compared ivonescimab against Keytruda in patients with first-line NSCLC with tumors that express PD-L1. The drug is already approved in China for this type of cancer, as well as two others , but has yet to be cleared in the U.S. for any indication. Ivonescimab met the key secondary goal of improving overall survival (OS). The companies previously announced the achievement of the main progression-free survival (PFS) endpoint in May 2024, earning the antibody the nickname Keytruda killer. The therapy achieved PFS of 11.14 months as compared to Keytruda’s 5.82 months. Lung cancer Summit shares descend as PD-1/VEGF asset misses early survival mark Summit Therapeutics planned an early interim progression-free survival readout for HARMONi-3 in the hope of enabling earlier regulatory engagement—but the early analysis delivered disappointment for the company and shareholders. May 4, 2026 · 2 min read · Tristan Manalac Read more “Akeso’s HARMONi-2 study has now demonstrated both PFS and OS superiority versus Keytruda in China, raising the possibility that future NSCLC regimens may increasingly be judged against ivonescimab rather than Keytruda,” Jefferies wrote in a Thursday morning note. “While investors can reasonably debate whether China data will fully translate globally,” the analysts continued, “this latest OS readout strengthens the case for ivonescimab as a potential next-generation immunotherapy backbone in NSCLC.” Summit’s shares rose over 7% to $15.65 in early morning trading Thursday. Akeso did not reveal detailed data on the OS endpoint but promised to do so at a future medical meeting and in a peer-reviewed journal. In the meantime, Summit is working on confirming these achievements in trials conducted elsewhere. A key test will be the outcome of the global Phase 3 HARMONi-3 trial , which is testing ivonescimab with chemotherapy against Keytruda in patients with first-line metastatic NSCLC. After the drug was approved for this indication in China, the regulator there released additional data on the label that suggested a degradation of the PFS benefit . Analysts raised concerns that the HARMONi-3 trial may not show a sufficient benefit to warrant an accelerated approval from the FDA. Summit is expected to reveal data from HARMONi-3 sometime this half. In May, an early interim analysis of PFS from HARMONI-3 failed to reach statistical significance, postponing Summit’s plans for a regulatory filing in this indication. Summit is, however, currently awaiting a November FDA decision for the therapy in NSCLC with mutations in the gene for epidermal growth factor receptor (EGFR). Immuno-oncology ASCO: Akeso’s VEGF/PD-1 boosts lung cancer survival, relieving pressure on US partner Summit Analysts, investors and partner Summit Therapeutics had all been keenly awaiting the overall survival update, after previous data from Akeso’s HARMONi-6 trial left them wanting. May 31, 2026 · 3 min read · Annalee Armstrong Read more

100 Deals associated with Pembrolizumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D10574	Pembrolizumab	L01XC18	DB09037

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Carcinoma of urinary bladder, invasive	European Union	Merck Sharp & Dohme BV	01 Jul 2026
Carcinoma of urinary bladder, invasive	Iceland	Merck Sharp & Dohme BV	01 Jul 2026
Carcinoma of urinary bladder, invasive	Liechtenstein	Merck Sharp & Dohme BV	01 Jul 2026
Carcinoma of urinary bladder, invasive	Norway	Merck Sharp & Dohme BV	01 Jul 2026
Platinum-Resistant Fallopian Tube Carcinoma	China	Merck Sharp & Dohme LLC	23 Jun 2026
Platinum-Resistant Primary Peritoneal Carcinoma	European Union	Merck Sharp & Dohme BV	22 Apr 2026
Platinum-Resistant Primary Peritoneal Carcinoma	Iceland	Merck Sharp & Dohme BV	22 Apr 2026
Platinum-Resistant Primary Peritoneal Carcinoma	Liechtenstein	Merck Sharp & Dohme BV	22 Apr 2026
Platinum-Resistant Primary Peritoneal Carcinoma	Norway	Merck Sharp & Dohme BV	22 Apr 2026
Platinum-Resistant Epithelial Ovarian Carcinoma	European Union	Merck & Co., Inc.	02 Apr 2026
Platinum-Resistant Epithelial Ovarian Carcinoma	Iceland	Merck & Co., Inc.	02 Apr 2026
Platinum-Resistant Epithelial Ovarian Carcinoma	Liechtenstein	Merck & Co., Inc.	02 Apr 2026
Platinum-Resistant Epithelial Ovarian Carcinoma	Norway	Merck & Co., Inc.	02 Apr 2026
Mismatch repair-deficient Colonic Cancer	United States	Merck Sharp & Dohme Corp.	10 Feb 2026
Mismatch repair-deficient Colonic Cancer	United States	Merck Sharp & Dohme LLC	10 Feb 2026
Neoplasms	United States	Merck Sharp & Dohme Corp.	10 Feb 2026
Neoplasms	United States	Merck Sharp & Dohme LLC	10 Feb 2026
Ovarian Cancer	United States	Merck Sharp & Dohme LLC	10 Feb 2026
Ovarian Cancer	United States	Merck Sharp & Dohme Corp.	10 Feb 2026
Muscle Invasive Bladder Carcinoma	United States	Merck Sharp & Dohme Corp.	21 Nov 2025

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Recurrent Platinum-Resistant Ovarian Carcinoma	NDA/BLA	United States	Merck & Co., Inc.	20 Oct 2025
Small intestine carcinoma	NDA/BLA	European Union	Merck Sharp & Dohme Corp.	25 Mar 2022
Non-small cell lung cancer stage I	Phase 3	United States	Merck Sharp & Dohme LLC	04 May 2026
Non-small cell lung cancer stage I	Phase 3	Australia	Merck Sharp & Dohme LLC	04 May 2026
Non-small cell lung cancer stage I	Phase 3	Canada	Merck Sharp & Dohme LLC	04 May 2026
Non-small cell lung cancer stage I	Phase 3	France	Merck Sharp & Dohme LLC	04 May 2026
Non-small cell lung cancer stage I	Phase 3	Germany	Merck Sharp & Dohme LLC	04 May 2026
Non-small cell lung cancer stage I	Phase 3	Greece	Merck Sharp & Dohme LLC	04 May 2026
Non-small cell lung cancer stage I	Phase 3	Hungary	Merck Sharp & Dohme LLC	04 May 2026
Non-small cell lung cancer stage I	Phase 3	Israel	Merck Sharp & Dohme LLC	04 May 2026

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02617849 (Pubmed \| Oncoimmunology)	Phase 2	Melanoma	30	Pembrolizumab and Carboplatin/ Paclitaxel	zlryhnsdct(ocyyljumkz) = gcyheysipr kuqofyucel (xmgmayhmsh ) View more	Negative	31 Dec 2026
WCLC2026	Not Applicable	Advanced Lung Non-Small Cell Carcinoma	331	Camrelizumab	akcraxzdpm(mkmleekjig): P-Value = 0.534 View more	Positive	12 Sep 2026
				Pembrolizumab
WCLC2026	Not Applicable	metastatic non-small cell lung cancer PDL1-high	246	Pembrolizumab	dcarnkyrxc(nvxldscuag) = vqkuokhqcy zkyoovnwov (esftchbssr ) View more	Positive	12 Sep 2026
NCT06155279 (CHIMERA, WCLC2026)	Phase 2	Malignant Pleural Mesothelioma Neoadjuvant	41	Pembrolizumab plus pemetrexed and cisplatin or carboplatin	gumhqszlqk(oqnshqunfr) = khxzdwhztf ryboixfqfx (xxqggdjtpb ) View more	Negative	12 Sep 2026
KEYNOTE-189 (WCLC2026)	Phase 3	metastatic non-small cell lung cancer First line	1,175	Pembrolizumab plus chemotherapy	nypoqpdkfb(jvvhrloqhh) = hczsxyhigg zqavsnfohi (fsuudzujdy, 12.7 - 20.0)	Positive	12 Sep 2026
				Chemotherapy	nypoqpdkfb(jvvhrloqhh) = bphwkawjgg zqavsnfohi (fsuudzujdy, 3.3 - 10.3)
WCLC2026	Not Applicable	Non-Small Cell Lung Cancer	61	preoperative chemoradiotherapy (CRT)	fguggjkiue(luxrtgmiin): P-Value = 0.128 View more	Positive	12 Sep 2026
				perioperative immune checkpoint inhibitors (stage II-III NSCLC)
WCLC2026	Not Applicable	MET gene amplification Non-small Cell Lung Cancer First line MET Amplification \| PD-L1 Expression	4	savolitinib	lejfelvspv(lpdgpvsriv) = xwjcnrzntq flmnorgdgq (tgatebogkw )	Positive	12 Sep 2026
				carboplatinnab-paclitaxel + carboplatinnab-paclitaxel + carboplatinnab-paclitaxel	lejfelvspv(lpdgpvsriv) = gzxvgdirlm flmnorgdgq (tgatebogkw )
KEYNOTE-024 (WCLC2026)	Not Applicable	Non-Small Cell Lung Cancer PD-L1	369	Pembrolizumab-based treatment (Completion group)	ppqzzwzjwg(jehbysomhj) = bnbrirxfpq tburfcmpti (rtmjxsllgx ) View more	Positive	12 Sep 2026
				Pembrolizumab-based treatment (Discontinuation group)	ppqzzwzjwg(jehbysomhj) = iwwjhtxbnd tburfcmpti (rtmjxsllgx ) View more
WCLC2026	Phase 3	metastatic non-small cell lung cancer First line	321	Pembrolizumab with chemotherapy	epcmvrznhx(trnwpyhmmd): HR = 0.8 (95.0% CI, 0.66 - 0.96)	Positive	12 Sep 2026
				Ipilimumab-nivolumab plus chemotherapy
WCLC2026	Not Applicable	Non-Small Cell Lung Cancer Neoadjuvant	110	Neoadjuvant regimens included tislelizumab/pembrolizumab/mixed	kqnryygzwj(exkzlxaicn) = wgcorzycwx kfdmryljwl (lpwebvyshn ) View more	Positive	12 Sep 2026

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data